Relypsa Inc (RLYP)

31.99
0.02 0.06
Prev Close 31.97
Open 31.99
Day Low/High 31.97 / 32.04
52 Wk Low/High 10.26 / 32.12
Volume 2.43M
Avg Volume 3.23M
Exchange
Shares Outstanding 44.88M
Market Cap 1.44B
EPS -4.40
Div & Yield N.A. (N.A)

Latest News

Synergy, Portola Still in My Sights

Synergy, Portola Still in My Sights

Both pharma companies are promising names that easily could become buyout targets.

Biotechs Rally on Pfizer/Medivation Deal

The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...

3 Biotech-Investing Mistakes to Avoid

3 Biotech-Investing Mistakes to Avoid

These are the biggest errors that I've made over the years.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

I'm Bullish on Biotechs

The market continues to trade lower as we late morning, with Tobira Therapeutics serving as the "disaster du jour" in the small-cap biotech space. This stock is trading down some 60% after its midstage compound targeting non-alcoholic steatohepatiti...

Synergy Pharma Offers Lots of Synergies

Synergy Pharma Offers Lots of Synergies

I expect Allergan or another player to bid for SGYP soon.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Relypsa Stock Surges on $1.53 Billion Galenica Takeover Offer

Relypsa Stock Surges on $1.53 Billion Galenica Takeover Offer

Shares of Relypsa surged on news of a takeover by Galenica, the owner of Switzerland's biggest pharmacy network.

4 Small-Cap Biotechs With Big Stories to Tell

4 Small-Cap Biotechs With Big Stories to Tell

Watch these names as stability returns to the sector.

Morning Movers: GM, JOY, RLYP, BIIB

Morning Movers: GM, JOY, RLYP, BIIB

General Motors crushed Wall Street earnings estimates before the opening bell.

A Mid-Year Look at 4 Best Ideas Picks

A Mid-Year Look at 4 Best Ideas Picks

I still like and own these small-caps.

5 Small-Cap Favorites Are Moving on Up

5 Small-Cap Favorites Are Moving on Up

Updates on smaller housing, retail and biotech plays recently mentioned on these pages.

Ardelyx Has Big Potential

Ardelyx Has Big Potential

This small-cap company's shares are half where they ended 2015.

4 Possible Acquisition Targets in Biotech

4 Possible Acquisition Targets in Biotech

These mid-caps would do well by themselves, but could tempt bigger companies.

First-Quarter GDP Revised Upward; Futures Indicate Higher Opening

Also, Thermo Fisher annouces an acquisition as takeover talks boost Valeant shares. 

Bret Jensen Reporting for Duty

Good morning! Bret Jensen here! It's good to be standing in for Doug Kass on Doug's Daily Dairy this Friday, especially on a day when my "Best Idea" Relypsa (RLYP) is likely to soar. After the bell Thursday, the U.S. Food and Drug Administration ess...

2 Promising Biopharmas Reach Key Junctures

2 Promising Biopharmas Reach Key Junctures

FDA decision will impact Relypsa's buyout potential while Aritana won't stay this undervalued.

Biotech Is Showing Some Bargains

Biotech Is Showing Some Bargains

It is hard to see much growth in the market overall, until earnings growth returns.

Biotech Is Ripe for M&A: Analysts

After an asset price drop, large pharmaceutical companies are looking for strategic purchases.

Looking Back at Biotech and Housing Small-Caps

Looking Back at Biotech and Housing Small-Caps

I continue to like RLYP, TPH and LGIH.

4 Possible Biotech M&A Targets

4 Possible Biotech M&A Targets

These concerns are well on their way to FDA approval for their first commercialized products in addressable markets.

M&A Could Ignite Next Leg Up for Biotech

M&A Could Ignite Next Leg Up for Biotech

Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.

Relypsa's Still a Bargain Despite 67% Rally

Small biotech has plenty of cash and a very valuable drug.

A Good Morning So Far

The market is off to a good start, as the futures had portended earlier. Industrial and construction stocks seem to be doing particularly well. Rail-car maker Greenbrier Cos. (GBX) continues to show strength even after a recent earnings report that ...

Relypsa's Still a Bargain Despite 67% Rally

Relypsa's Still a Bargain Despite 67% Rally

Small biotech has plenty of cash and a very valuable drug.

Bret Jensen Reporting for Duty

Good morning -- Bret Jensen here! As always, it's good to be standing in for Doug Kass. It looks like the rollercoaster in the market will continue today. We had a nice rally on Wednesday, followed by a deep decline yesterday. And this morning, the ...